Hagens Berman has opened an investigation into CVRx Inc. following a U.S. Department of Justice Civil Investigative Demand related to potential false claims and kickbacks involving its heart failure device, Barostim. The company also revealed severe operational problems including a major cut in 2026 revenue guidance, sales force disruptions, and a sharp drop in Medicare Advantage approvals. These issues led to a 59% stock price drop and the sudden firing of CVRx's Chief Revenue Officer. The investigation will explore whether CVRx misled investors about its sales and reimbursement status and if the DOJ probe is linked to the CRO's termination.
The story about CVRx Inc. follows a significant 59% stock drop. For readers following the health sector, here is Pluang's market snapshot as of Oct 01, 2026 23:41 WIB: out of 100 priced US health stocks, 22 rose and 78 fell. Bio-Rad Laboratories (BIO) traded at USD 362.41 with a 4.05% decline and a typical hold time of 58 days, Regeneron Pharmaceuticals (REGN) at USD 728.69 down 3.90% with a longer hold time of 106 days, and Canopy Growth Corp (CGC) at USD 0.87 down 3.35% with a shorter hold time of 39 days. Pluang order activity showed strong buying interest in BIO and REGN with 100% buy orders, while CGC had 92% buy orders.
Foghorn Therapeutics saw its price target cut from $12 to $5 after it and Eli Lilly decided not to advance key cancer drug programs. The companies will not continue development of FHD-909 or a selective SMARCA2 degrader, ending their collaboration. F...
RPM International is set to report its Q3 2026 earnings on October 6, with analysts forecasting earnings per share of $1.95 and revenue of $2.22 billion, both higher than the previous year. Despite a slight recent dip in the EPS estimate, the report ...
Jefferies increased its price target for Regeneron to $930, citing an expanded partnership with Sanofi to develop four new long-acting antibodies targeting inflammatory pathways. Sanofi will pay Regeneron $1 billion upfront, with potential milestone ...
McCormick & Company reported fiscal Q3 results with adjusted EPS of $0.86, surpassing estimates of $0.76, and revenue of $2.02 billion, up 17.4% from last year. Growth was driven by the McCormick de Mexico acquisition, pricing actions, and favorable ...
Aehr Test Systems is set to report Q3 earnings of $0.11 per share and revenue around $27 million, marking a 1,000% increase in earnings year-over-year. The company projects fiscal 2027 revenue growth between 160% and 200%, reaching $130-$150 million,...
